Document is current
Any future updates will be listed below
-
Authors
Tu, Haochen
Hosaka, Aoi
Hichiwa, Genki
Wang, Yayan
Kazuki, Kanako
Tabata, Toshiaki
Osaki, Mitsuhiko
Nakayama, Yuji
Kanazawa, Iori
Honma, Kazuhisa
Kimura, Makoto T.
Gao, Xu
Ogata, Norichika
Abe, Satoshi https://orcid.org/0000-0003-1153-0720
Oshimura, Mitsuo https://orcid.org/0000-0003-2640-7039
Kazuki, Yasuhiro https://orcid.org/0000-0003-4818-4710
-
Funding
Funding for this research was provided by:
JST SPRING (JPMJSP2187)
Japan Agency for Medical Research and Development (JP25am0521002)
Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences (21-101)
- License Information
-
More Information
Article History
Received: 8 October 2025
Accepted: 11 March 2026
First Online: 20 March 2026
Declarations
:
: The experimental protocol, involving the use of commercially available hUC-MSCs and their genetic modification, was approved by the Institutional Gene Recombination Experiment Safety Committee at Tottori University (Approval Number: [35 − 024, 35–044, 35–093, 2024-008, 2024-063, 2024-081, 2025-011, and 2025-042]). hUC-MSCs were purchased from ATCC (PCS-500-010), and detailed information is available on the company’s website [ ].
: Not applicable.
: M. Osh. is the Chief Executive Officer and a shareholder of Trans Chromosomics, Inc., and POC Inc. I.K. and K.H. are employees of Trans Chromosomics, Inc. M.T.K. is an employee of RMDC Inc. T.T. is an employee of POC Inc. The other authors declare no competing interests.
